About Us
Projects and Technology
Governance
Investors
Media
Contact

About Us
Projects and Technology
Corporate Governance
Investors
Media
Contact

Financial Reports and Presentations

2006

2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2005
1970
All years

Type of information

Interim reports
Annual reports
Presentations
Other

	Report
December 10, 2006Interim Report May – October 2006
August 14, 2006Annual Report 2005 / 2006

Share this page

Investor contact

[email protected]

+46 18-50 54 40

Subscribe to our news

Investors

Now enrolling:

Paccal Vet hemangiosarcoma trial

A clinical study for dogs with splenic hemangiosarcoma

Learn more and take survey to see if you may qualify

Take me there

About Us
Projects and Technology
Corporate Governance
Investors
Media
Contact

Vivesto is a Swedish development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential. The project portfolio consists of Cantrixil and Docetaxel micellar, which are being developed for blood cancer and prostate cancer, respectively, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma.

The Share

Follow the share

Personal data
Cookies

OAS-MA-P-001-SEP2020

Box 3061
169 03 Solna, Sweden

Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@vivesto.com